Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Liver cancer cell inhibitor

A liver cancer cell and inhibitor technology, applied in medical preparations containing active ingredients, organic active ingredients, drug combinations, etc., can solve problems such as high recurrence rate, poor prognosis, and limited treatment

Active Publication Date: 2021-07-16
TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the life expectancy of patients with advanced liver cancer treated with sorafenib is only 8-11 months
Despite remarkable progress in conventional treatment options for patients with liver cancer over the past few decades, it remains one of the deadliest malignancies worldwide due to limited treatment, poor prognosis, and high recurrence rate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liver cancer cell inhibitor
  • Liver cancer cell inhibitor
  • Liver cancer cell inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Embodiment 1, HTBPI and / or BA1 anti-liver cancer activity experiment

[0057] 1. Preparation of liver cancer cell inhibitors

[0058] This embodiment provides three liver cancer cell inhibitors, namely inhibitor B, inhibitor H and inhibitor HTBPI+BA1. The active ingredient of inhibitor B is BA1, the active ingredient of inhibitor H is HTBPI, and the active ingredient of inhibitor HTBPI+BA1 is BA1 and HTBPI. In the inhibitor HTBPI+BA1, the molar ratio of BA1 and HTBPI is 1:2000. The preparation methods of these 3 liver cancer cell inhibitors are as follows:

[0059] 1.1 Preparation of Inhibitor H

[0060]HTBPI was dissolved in dimethyl sulfoxide (DMSO) to prepare a 10 mmol / L stock solution, and stored in an aliquot at -20°C, and diluted with DMEM medium containing 10% FBS and 1% penicillin / streptomycin. The stock solution is used to obtain the HTBPI solution, which is the inhibitor H. In the HTBPI solution, the HTBPI content is 40 μmol / L (40000 nmol / L).

[0061] 1....

Embodiment 2

[0083] Embodiment 2, HTBPI anti-liver cancer activity

[0084]1. HTBPI inhibits the growth of hepatocellular carcinoma and promotes the apoptosis of hepatocellular carcinoma

[0085] The cell viability was measured by CCK-8 method, and the growth inhibitory effect of HTBPI on two typical human liver cancer cell lines (HepG2, Hep3B) was analyzed. HepG2 and Hep3B cells were planted in the logarithmic growth phase, and then treated with HTBPI 0, 2.5, 5, 10, and 20 μM for 24 hours, and the cell viability was measured by the CCK-8 method. The results showed that HTBPI-treated liver cancer Cell viability had a time-dependent downward trend ( Figure 7 ). The HepG2 and Hep3B treated with HTBPI for 24 hours were taken for monoclonal formation test, and the results showed that HTBPI treated HepG2 and Hep3B for 24 hours could significantly inhibit the cell proliferation of HepG2 and Hep3B ( Figure 8 , the blank group was treated with 0 μM HTBPI for 24 hours, and the HTBPI group was ...

Embodiment 3

[0095] Example 3. Inhibition of autophagy can further promote the apoptosis of HTBPI-induced liver cancer cells

[0096] To study the relationship between apoptosis and autophagy, it was found in this study that the autophagy inhibitor BA1 can further promote the apoptosis of HCC cells induced by HTBPI ( Figure 14 ). The specific method is as follows: take the control treated cells of HepG2 in Example 1, the HTBPI treated cells of HepG2 alone, the BA1 treated cells of HepG2 alone, the HTBPI and BA1 combined treated cells of HepG2, the controlled treated cells of Hep3B, the HTBPI treated cells of Hep3B alone , BA1 of Hep3B treated cells alone and HTBPI of Hep3B combined with BA1 and analyzed by Western blot.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a liver cancer cell inhibitor. The liver cancer cell inhibitor contains HTBPI or a pharmaceutically acceptable salt thereof. The liver cancer cell inhibitor can also contain bavalomycin A1. The cell death increase rate of the two hepatoma carcinoma cells HepG2 and Hep3B jointly treated by HTBPI and BA1 is obviously higher than the sum of the cell death increase rate of the cells independently treated by HTBPI and the cell death increase rate of the cells independently treated by BA1. The apoptosis increase rate of the two hepatoma carcinoma cells HepG2 and Hep3B jointly treated by HTBPI and BA1 is obviously higher than the sum of the apoptosis increase rate of the HepG2 cells independently treated by HTBPI and the apoptosis increase rate of the HepG2 cells independently treated by BA1. The hepatoma carcinoma cell inhibitor HTBPI+BA1 has remarkable inhibitory activity on hepatoma carcinoma cells, BA1 remarkably enhances the anti-hepatoma activity of HTBPI, HTBPI remarkably enhances the anti-hepatoma activity of BA1, and BA1 and HTBPI generate a synergistic effect in the anti-hepatoma aspect. The inhibitor can be used for treating or / and preventing the liver cancer.

Description

technical field [0001] The invention relates to an inhibitor of liver cancer cells in the field of medicine. Background technique [0002] Bafilomycin A1 is a macrolide antibiotic derived from Streptomyces griseus with molecular formula C 35 h 58 o 9 , is a specific inhibitor of vacuolar H+-ATPase, and has antibacterial, antifungal, and antitumor effects. [0003] Primary liver cancer (PLC), as a clinically common malignant tumor of the digestive system, is the sixth most common tumor and the second leading cause of cancer death in the world, among which hepatocellular carcinoma (HCC) is the most common. Since most patients with primary hepatocellular carcinoma have basic hepatitis diseases and poor liver function, they are prone to relapse after local treatment. When they are diagnosed, they are already in the advanced stage, with rapid progression, poor prognosis and short average survival time. At present, the treatment strategies for liver cancer are not satisfactory...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61K31/4745A61P35/00
CPCA61K31/365A61K31/4745A61P35/00A61K2300/00
Inventor 于海洋庞旭邱玉玲王涛刘宏伟高秀梅吴红华陈璐姜苗苗刘二伟
Owner TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com